Home / Research library / MOTS-c
MOTS-c: molecular data, studies & sources
MOTS-c is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C101H152N28O22S2
- Molecular weight (MW)
- 2174.6 g/mol
- PubChem compound ID
- 146675088
- Record title
- Mots-c
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 146675088 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
- InChIKey
- WYTHCOXVWRKRAH-LOKRTKBUSA-N
- SMILES
- CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCSC)N
Identifiers & sequence
- PubChem CID
- 146675088
- CAS Registry Number
- 1627580-64-6via ChemIDplus, FDA GSRS
- FDA UNII
- A5CV6JFB78
- InChIKey
- WYTHCOXVWRKRAH-LOKRTKBUSA-N
Peptide sequence · 16 residues (one-letter code; X marks a residue without a one-letter code)
MRWQEMGYIFYPRKLR
Condensed notation with terminal groups and non-standard residues
H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH
Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 2173.1077 Da |
|---|---|
| Heavy atoms | 153 |
| Hydrogen-bond donors | 31 |
| Hydrogen-bond acceptors | 27 |
| Rotatable bonds | 70 |
| Topological polar surface area | 839.4 Ų |
| Calculated logP (Crippen) | -2.68 |
| Rings | 6 |
| Stereocenters | 16 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Drugs@FDA lists no NDA, BLA or ANDA with MOTS-c as an active ingredient (names searched: MOTS-C; checked October 7, 2026). Research-labelled MOTS-c listings are not FDA-approved drugs.
An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: No INN; the peptide name MOTS-c was searched.
Source: Drugs@FDA via openFDA (active-ingredient search for MOTS-C) · checked . openFDA data are not intended for clinical decisions.
Registered clinical trials
Studies registered on ClinicalTrials.gov that list MOTS-c as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
1 registered study matched, 1 currently active or recruiting.
- By highest phase
- Phase 2 · 1
- By registry status
- Recruiting · 1
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/ObesityNCT07505745 · start 2026-02-02 · primary completion 2027-02-14 | Phase 2Recruiting | Prediabetes · Insulin Resistance · Overweight/Obesity | Hudson Biotech120 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received MOTS-c, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.
Human studies that measured MOTS-c or used it as a comparator
Indexed as human studies in PubMed, but participants were not given MOTS-c as the studied intervention, or the record does not establish that they were. They describe measurements or comparisons, not the effect of administering the compound.
- Human study · PubMed trial index Endogenous level measured · not given
Circulating levels of MOTS-c in patients with breast cancer treated with metformin.
Cuyàs E, Verdura S, Martin-Castillo B et al. · Aging · 2022
PMID 36490309 · DOI: 10.18632/aging.204423
- Human study · PubMed trial index Endogenous level measured · not given
Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.
Dieli-Conwright CM, Sami N, Norris MK et al. · Scientific reports · 2021
PMID 34413391 · DOI: 10.1038/s41598-021-96419-z
- Human study · PubMed trial index Endogenous level measured · not given
Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.
Elhusseiny R, Ihsan M, Labidi M et al. · Medicine and science in sports and exercise · 2025
PMID 40674654 · DOI: 10.1249/MSS.0000000000003825
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Review · secondary evidence
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.
Zheng Y, Wei Z, Wang T et al. · Frontiers in endocrinology · 2023
PMID 36761202 · DOI: 10.3389/fendo.2023.1120533
- Research publication · design requires review
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Lee C, Zeng J, Drew BG et al. · Cell metabolism · 2015
PMID 25738459 · DOI: 10.1016/j.cmet.2015.02.009
- Research publication · design requires review
Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.
Yin Y, Li Y, Ma B et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
PMID 39321430 · DOI: 10.1002/advs.202405620
MOTS-c supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
MOTS-c for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Blank PeptidesUSD | 10mg Vial1 recorded offers | 10mg Vial · $55.00Stale observation · Checked Sep 30, 2026Supplier listing, MOTS-c 10mg Vial, Blank Peptides, opens in a new tab |
| American PeptidesUSD | 10mg Vial · 40mg Vial2 recorded offers | 10mg Vial · $100.00Recorded out of stock · Checked Nov 6, 2026Supplier listing, MOTS-c 10mg Vial, American Peptides, opens in a new tab |
| Amino ClubUSD | 10mg Vial · 40mg Vial2 recorded offers | 10mg Vial · $39.99Stale observation · Checked Oct 14, 2026Supplier listing, MOTS-c 10mg Vial, Amino Club, opens in a new tab |
| Nova Peptide SupplyUSD | 10mg Vial · 40mg Vial2 recorded offers | 10mg Vial · $49.99Checked Nov 6, 2026Supplier listing, MOTS-c 10mg Vial, Nova Peptide Supply, opens in a new tab |
| Amino USAUSD | 10mg Vial · 40mg Vial2 recorded offers | 10mg Vial · $50.00Checked Nov 6, 2026Supplier listing, MOTS-c 10mg Vial, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 40mg Vial · 10mg Vial2 recorded offers | 40mg Vial · $189.99Checked Nov 6, 2026Supplier listing, MOTS-c 40mg Vial, Cenexa Labs, opens in a new tab |
| LA PeptidesUSD | 10mg Vial · 20mg Vial · 40mg Vial3 recorded offers | 10mg Vial · $69.99Checked Nov 3, 2026Supplier listing, MOTS-c 10mg Vial, LA Peptides, opens in a new tab |
Reference sources & further reading
- PubChem compound record 146675088 — chemical identity and structure.
- FDA Global Substance Registration System: UNII A5CV6JFB78 — substance identity, names and codes.
- Wikipedia: MOTS-c — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
5-Amino-1MQ
C10H11N2+
159.21 g/mol · PubChem CID 950107
3 selected publications · 0 human intervention studies
FOXO4-DRI
C228H388N86O64
5358 g/mol · PubChem CID 167312269
4 selected publications · 0 human intervention studies
GHK-Cu
C14H23CuN6O4+
402.92 g/mol · PubChem CID 71587328
1 selected publication · 0 human intervention studies · 1 registered trial
Glutathione
C10H17N3O6S
307.33 g/mol · PubChem CID 124886
7 selected publications · 3 human intervention studies · 37 registered trials
Small molecule · highest stage: Phase 3
Humanin
C119H204N34O32S2
2687.2 g/mol · PubChem CID 16131438
1 selected publication · 0 human intervention studies
L-Carnitine
C7H15NO3
161.20 g/mol · PubChem CID 10917
8 selected publications · 0 human intervention studies · 40 registered trials
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)